$GEMP gemcabene Phase 3 planned

Gemphire Therapeutics (GEMP) announces plans to advance gemcabene into Phase 3 clinical development after data showed clinically meaningful reductions in LDL-C and hsCRP across multiple trials. The micro cap stock rose 13% in low volume, in after hours trade.

Check out detailed news in our Daily Pharma Scoop at SeekingAlpha Marketplace.